key: cord-0807708-d5caadbx authors: Johnsen, Stine; Sattler, Stefan M.; Miskowiak, Kamilla Woznica; Kunalan, Keerthana; Victor, Alan; Pedersen, Lars; Andreassen, Helle Frost; Jørgensen, Barbara Jolanta; Heebøll, Hanne; Andersen, Michael Brun; Marner, Lisbeth; Hædersdal, Carsten; Hansen, Henrik; Ditlev, Sisse Bolm; Porsbjerg, Celeste; Lapperre, Thérèse S. title: Descriptive analysis of long COVID sequela identified in a multidisciplinary clinic serving hospitalised and non-hospitalised patients date: 2021-04-29 journal: ERJ Open Res DOI: 10.1183/23120541.00205-2021 sha: 8cc840dcbee58850e4d626dc8f041df65d79bdbf doc_id: 807708 cord_uid: d5caadbx BACKGROUND: There is emerging data of long-term effects of COVID-19 comprising a diversity of symptoms. The aim of this study was to systematically describe and measure pulmonary and extra- pulmonary post COVID-19 complications in relation to acute COVID-19 severity. METHODS: Patients attending a standard of care 3-months post-hospitalisation follow-up visit, and those referred by their general practitioner because of persistent post-COVID-19 symptoms were included. Patients underwent symptomatic, quality of life, pulmonary (lung function and HRCT), cardiac (high resolution ECG), physical (1-MSTST, handgrip strength, CPET) and cognitive evaluations. RESULTS: All 34 hospitalised and 22 out of 23 non-hospitalised patients had≥1 complaint or abnormal finding at follow-up. 67% of patients were symptomatic (MRC ≥2 or CAT ≥10), with no difference between hospitalised versus non-hospitalised patients. Pulmonary function (FEV1 or DLCO) <80% of predicted) was impaired in 68% of patients. DLCO was significantly lower in those hospitalised compared to non-hospitalised (70.1±18.0 versus 80.2±11.2% predicted, p=0.02). 53% had an abnormal HRCT (predominantly groundglass opacities) with higher composite CT-scores in hospitalised versus non-hospitalised patients (2.3 [0.1, 4.8] and 0.0 [0.0, 0.3], p<0.001). 1-MSTST was below the 25th percentile in almost half of patients, but no signs of cardiac dysfunction were found. Cognitive impairments were present in 59–66% of hospitalised and 31–44% of non-hospitalised patients (p=0.08). CONCLUSION: Three months after COVID-19 infection, patients were still symptomatic and demonstrated objective respiratory, functional, radiological and cognitive abnormalities, which were more prominent in hospitalised patients. Our study underlines the importance of multidimensional management strategies in these patients. Without doubt the COVID-19 pandemic will cast a long shadow into the future. With increasing number of patients who have survived the disease, it is necessary to attain a better understanding of the long-term health complications of COVID-19. The lungs are often the first target organ of SARS-CoV-2 infection, but we now know that the virus can spread to many different organs (1) (2) (3) (4) . Experience from previous coronavirus outbreaks such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) suggest that some patients will experience long-term complications (5) . Reports of long-term effects of COVID-19, also referred to as long COVID have begun to be published in more severe hospitalised and less severe non-hospitalised patients (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . The predominant persistent symptoms include breathlessness, cough and fatigue. In addition, lung function and chest CT changes may be impaired months after the infection (9) . There is also compiling evidence for neurological complications of COVID-19, especially among the severely affected patients including loss of smell and taste, tingling sensations, dizziness, severe fatigue, as well as more severe outcome (16) (17) (18) . A large proportion of COVID-19 patients may also experience persistent cognitive impairments for months after their recovery (8) . The diversity of symptoms suggests both pulmonary as well as extrapulmonary involvement in long COVID. It is clearly crucial to understand not only the relative incidence of symptoms and abnormal findings from different organ system, but also to which extent they overlap and relate to the severity of acute CVID-19. In addition, the distribution and mechanisms of post-COVID complications may differ between long COVID patients that were hospitalised and those nonhospitalised during acute COVID-19. Being affected by more than one type of organ dysfunction significantly contributes to the overall burden of disease and may impact the speed by which patients return to normal life after their COVID-19 illness. Hence, the aim of this study was to systematically examine both long-term pulmonary and extrapulmonary function, in a cohort of hospitalised and non-hospitalised patients who had Methods are reported in brief and detailed information can be found in the online supplement. Type and degree of respiratory symptoms were assessed using the chronic obstructive pulmonary disease (COPD) assessment test (CAT) and Medical Research Council dyspnoea score (MRC). References found in supplemental methods. Work productivity and activity impairment questionnaire (WPAI) and the EQ-5D-5L quality of life HRCT images were obtained in inspiration and expiration in supine position. HRCT was analysed using a scoring system as previously suggested by Søyseth et al (25) . Scans were reviewed in random order and in consensus by two chest radiologists. Both observers (HH & MBA) were blinded regarding clinical outcome. All items were scored from 0 to 12 (representing 0-100 % of lung parenchyma) at four anatomical levels. A total score was calculated by adding the scores for each finding ranging from 0 to 96. Objective performance-based cognitive functions were assessed with a brief (≈20 minutes) cognition test battery consisting of the Screen for Cognitive Impairment in Psychiatry Danish Version (SCIP-D) (26) and the Trail Making Test-Part B (TMT-B) (27) . Together, these tests measure verbal learning and memory, working memory, verbal fluency, processing speed, and executive function. For patient flow please see Figure 1 . The protocol was first offered only to patients who had been admitted to the hospital with severe COVID-19 illness, but it soon became evident through social media and requests from general practitioners that a similar offer to outpatients was necessary. Unofficially it therefore became possible for general practitioners to refer patients directly to our research protocol. An overview of impairment in the different domains are depicted in figure 2. In In Subjective self-reported cognitive difficulties on the CFQ were generally high, with 89% reporting large difficulties (scores ≥43, corresponding to ≥1 SD above mean of healthy controls (21)). In Table 3 we present lung function data and functional status data assessed at the three-months follow-up. Overall, 68 % of patients had reduced lung function based on FEV1 or DLCO <80% of predicted. DLCO was lower in hospitalized compared to outpatients (70 %18 predicted and 80% 11 predicted, respectively, p=0.023). This holds true when comparing admitted patients with and without oxygen therapy requirement during acute COVID-19 (66% and 79%, p=0.004). The group means of FEV1 were normal (> 80% predicted) for all patients also when divided into hospitalised and not hospitalised, lower in the patients who had been hospitalized (p=0.024) Exercise capacity was also evaluated by having the patients perform the 1-MSTST and maximal handgrip. As seen in Table 3 almost half of patients (44%) performed below the 25% percentile (compared to population-based reference values (28) in the one-minute SST and almost one-third of patients (28%) performed below the 25% percentile in handgrip dynamometry (compared to population-based reference values (29) . CPET was performed in a subset of 31 patients. Overall VO 2max was 27.5 (8.9) kg/ml/min, and only 2 patients had a VO2max <80% predicted, while 11 patients had a breathing reserve of less than 25%. CPET test was considered normal in fifty percent of all patients. Although not significant it was more often abnormal in the participants that had been hospitalised and requiring oxygen. In all patients it was either decreased physical fitness (N=11, 35.5%) or decreased ventilatory capacity (N=5, 16%) that was the main reason for their abnormal CPET. In figure 3 we present HRCT data at 3-months follow-up. Overall, 53% of patients had abnormalities on HRCT, and the median total HRCT score was 0. common pathology was ground-glass opacities, which was significantly higher in hospitalised than non-hospitalised patients (P<0.001). Cardiac evaluation (history, pro-BNP, 12 lead ECG high resolution ECG) was normal in all patients but one, who presented with chest discomfort at 3 months follow-up. He was diagnosed with non-ST-elevation myocardial infarction and underwent revascularization with stent implantation. Participants had a normal median pro-BNP 5.3 [2.7, 11.6] with no intergroup differences. Sinus rhythm was present in all patients but one in the hospitalised group who was known with atrial fibrillation prior to COVID-19. Evaluation of autonomic function showed DC and PRD in normal range for both groups. Objective performance-based and subjective self-reported cognition data are presented in Table 4 The percentage of patients with clinically significant cognitive impairment ranged from 51-58%, depending on the cut-off scores implemented for determining 'clinically relevant' impairment. Of these, 38-53 % of patients showed broad impairments (performance decline on a global cognition measure), and an additional 4-16% patients showed selective impairments (clinically relevant impairment on ≥2 of the 6 tests). The frequency of cognitive impairments ranged from 59-66% for hospitalised patients and 31-44% for non-hospitalised patients depending on the chosen cut-off. Further detail on cognitive results is provided in supplemental results. Correlations are depicted in figure 4 . Impaired lung function has been shown to persist in survivors of COVID-19 pneumonia with impaired DLCO being the most common abnormality (7, 30) , reflecting the pathophysiological changes seen in acutely ill patients. FEV1 in our patients was on average normal but significantly different between hospitalised versus non-hospitalised patients and is in accordance with a study of 57 patients evaluated thirty days after their COVID-19 disease (31) . Our data suggest lung function impairment even three months after COVID-19 and an association with hospitalisation, duration of hospitalisation and oxygen requirement. We found that hospitalisation and oxygen support resulted in radiologic abnormalities at three months follow-up. Hospitalised patients had higher CT-scores, reflecting more abnormalities, than non-hospitalised patients that were still present 3 month after COVID-19. Only one patient in the in the hospitalised group who had been intubated presented with fibrosis at follow-up. Our finding of predominately ground-glass opacities is in line with a recent study including 103 patients that ground-glass opacities in one out of four patients 3 month after COVID-19 (9) . Five patients in the hospitalised group showed mosaic attenuation, which may be indicative of perfusion defects. CT scan with contrast that excluded thrombosis. It has been hypothesized that pulmonary pathology in COVID-19 is in fact primarily a vascular thrombotic disease with microemboli being the driver of COVID-19 related ARDS (32) . In one study pulmonary DECT angiography revealed a significant number of pulmonary ischemic areas even in the absence of visible pulmonary arterial thrombosis(33) which may reflect microthrombosis associated with COVID-19 pneumonia. In our study we tested physical capacity by functional tests in the form of 1-MSTST, maximum handgrip and CPET (the latter in a subset of 31 patients) as decrease in these measures has been shown to be associated with mortality and quality of life in certain patient groups (34) and has been used to assess exercise-induced desaturation in patients with different pulmonary pathologies including interstitial pulmonary disease (35) . In short about half of patients doing 1-MSTS and one third of patients in the handgrip dynamometri performed below the 25% percentile of and age and sex-matched population and this was independent of whether or not patients had hospitalised. In line with this, only a small fraction of the patients had severe reduced ventilator capacity as measured by CPET while a larger fraction had reduced breathing reserved or deconditioning. We know from the previous SARS epidemic that patients had impairment in these tests primarily because of physical deconditioning (36) . Collectively, most studies find decreased physical function after COVID-19 illness at some level. Correspondingly, low level of physical capacity was detected in an Italian cohort of COVID 19 patients using 1-min SST among other tests (37) . In another recent study evaluating 124 patients at 3 months after COVID-19, although they did not find that patients had significantly decreased physical capacity evaluated with the 6MWD, they did find that 22 % of patients had low 6MWD(38). Patients in this study displayed objective performance difficulties on the cognitive tests, with 51-58% being clinically significant. Notably, subjective cognitive difficulties did not differ between hospitalised and non-hospitalised patients. Although the sample size of our patient cohort was moderate, this suggest that cognitive consequences of COVID-19 illness may not only be limited to the most severely affected patients. In keeping with this, internet-based testing of cognitive functions in > 80,000 people with suspected or biologically confirmed COVID-19 revealed most pronounced cognitive impairments in people who had been hospitalised with COVID-19 illness, but also mild impairments in biologically confirmed cases with no reported breathing difficulties (39) . Additionally, > 90% of our patient cohort presented with moderate to severe self-reported cognitive difficulties. This is in line with previous evidence for long-term subjective cognitive sequalae of COVID-19 (8) . Our findings thus add to the emerging evidence for cognitive consequences of COVID-19 in both hospitalised and non-hospitalised patients that may persist for several months and impede return to work and daily functioning. The most common persistent symptoms that patients in our study reported was dyspnoea and chest discomfort. Accordingly, an Italian study reported that 87 % of people discharged from hospital still experienced at least one symptom 2 months after their initial illness; the more common symptoms being fatigue, difficulty breathing, joint and chest pain (6) . Correspondingly Our study has some limitations. First, this was an observational, cross-sectional study at 3 months after COVID-19. Patients' conditions before COVID-19 were often unknown and clinical data during the initial hospital stay was only compiled to an extent as clinically necessary and systematically available from hospital records. Possibly abnormalities that we find are unrelated to patients COVID-19 illness and may have been pre-existent. Furthermore, progression or regression of longterm consequences cannot be evaluated yet. Secondly, the study suffers from a selection bias, as non-hospitalised patients were referred by their general physician because of symptoms. On the other hand, sicker and frail patients may have refrained from study participation due to severe symptoms or fatigue. In addition, clinical and laboratory data from non-hospitalised patients during the acute phase were not available. Thirdly, we are aware that our patient cohort is small in size. However, patients in this study are very well characterized in terms of their post covid clinical status and complications, using a broad variety of objective tests. We considered these data important to report in order to raise awareness of for the very large number of patients that may suffer from Long COVID (also in primary care) and to offer the most suitable screening and followup program for long COVID patients. In conclusion, we demonstrate that three months after a COVID-19, the majority of patients showed signs of organ function impairment, underlining the importance of multidimensional management strategies in these patients. Most noteworthy impairment was seen in cognition and quality of life regardless of hospitalisation and alterations in HRCT of the chest and impaired DLCO that were present in hospitalised patients. Patients, even though not hospitalised, may still experience reduction in quality of life and perceived health. An important outcome of the data presented here is that it has successfully contributed to the facilitation of establishment of post-covid clinics on a national basis as well as formed our standard of care follow-up program. First wawe of COVID-19 hospital admission in Denmark: a Nationwide population-based cohort study Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response COVID-19 pneumonia: Microvascular disease revealed on pulmonary dual-energy computed tomography angiography. Quantitative Imaging in Medicine and Surgery Epidemiology and clinical characteristics of COVID-19 The 1-Year Impact of Severe Acute Respiratory Syndrome on Pulmonary Function, Exercise Capacity, and Quality of Life in a Cohort of Survivors* Persistent symptoms in patients after acute COVID-19 Respiratory follow-up of patients with COVID-19 pneumonia COVID-19 " Long Hauler lung function and CT findings three months after hospital admission for COVID-19. The European respiratory journal Management of post-acute covid-19 in primary care Pulmonary function and radiological features four months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study Mediumterm impact of COVID-19 on pulmonary function, functional capacity and quality of life Diffusion Capacity Abnormalities for Carbon Monoxide in Patients with COVID-19 At Three-Month Follow-up More than 50 Long-Term Effects of COVID-19: A Systematic Review and Meta-Analysis 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study COVID-19 presenting as stroke Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young Neurologic and Immunologic Complications of COVID-19 Term Risk Factors for Alzheimer's Disease The post-COVID-19 functional status scale: A tool to measure functional status over time after COVID-19 The cognitive failures questionnaire (CFQ) and its correlates ERS guidelines, statements and technical standards published in the ERJ in 2014: A year in review The one repetition maximum test and the sit-to-stand test in the assessment of a specific pulmonary rehabilitation program on peripheral muscle strength in COPD patients Cardiopulmonary exercise testing and its application Diagnosis of biopsy verified usual interstitial pneumonia by computed tomography Optimising screening for cognitive dysfunction in bipolar disorder: Validation and evaluation of objective and subjective tools Army Test Battery. Army Individual Test Battery. Manual of directions and scoring. War Department, Adjutant General's office Populationbased reference values for the 1-min sit-to-stand test Reference values of handgrip dynamometry of healthy adults: A population-based study Long term respiratory complications of covid-19 Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19 COVID-19 pneumonia: Microvascular disease revealed on pulmonary dual-energy computed tomography angiography Prediction of long-term clinical outcomes using simple functional exercise performance tests in patients with COPD: A 5-year prospective cohort study The 1-minute sit-tostand test to detect exercise-induced oxygen desaturation in patients with interstitial lung disease The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status Low physical functioning and impaired performance of activities of daily life in COVID-19 patients who survived hospitalisation. The European respiratory journal. 2020. 38. van den Borst B Comprehensive health assessment three months after recovery from acute COVID-19 Cognitive deficits in people who have recovered from COVID-19 relative to controls: An N=84,285 online study. medRxiv Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? Medical Research Council dyspnea score CFQ, cognitive failures questionnaire; SCIP, screen for cognitive impairment in psychiatry PRD, periodic repolarization dynamics DC, deceleration capacity, VO2 max, maximal oxygen uptake, 1-MSTST, 1 minute sit and stand test Dr Sattler has nothing to disclose Dr Miskowiak reports personal feels from Lundbeck outside the submitted work Dr Kunalan has nothing to disclose Dr Victor has nothing to disclose Dr Pedersen has nothing to disclose Dr Andreassen has nothing to disclose Dr Jørgensen has nothing to disclose Dr Heebøll has nothing to disclose Dr Andersen has nothing to disclose Dr Marner has nothing to disclose Dr Haedersdal has nothing to disclose Dr Hansen has nothing to disclose Dr Ditlev has nothing to disclose Dr Porsbjerg has nothing to disclose Dr Lapperre has nothing to disclose Lapperre Supplemental Methods: Laboratory blood work: Standard blood tests included haemoglobin, leucocytes and white blood cell count, thrombocytes, C-reactive protein, ferritin, creatinine, urea, Potassium, Sodium, Calcium, alanine aminotransferase, alkaline phosphatase, lactate dehydrogenase, bilirubin, albumin, international normalized ratio Type and degree of respiratory symptoms were assessed using the chronic obstructive pulmonary disease (COPD) assessment test(1) and Medical Research Council dyspnoea score (MRC Work productivity and activity impairment questionnaire (WPAI)(3) and the EQ-5D-5L quality of life questionnaire(4,5) were obtained. In addition, the Post-COVID-19 functional status (PCFS) scale was completed(6) with ULsensor for flow/volume, diffusing capacity for carbon monoxide (DLCO) and transfer coefficient of the lung for carbon monoxide (KCO) were measured using Vyntus ONE DL (Vyaire Medical GmbH), for real time carbon monoxide and methane diffusion with UL sensor for flow Heart rate (bpm) and oxygen saturation (SaO 2 ) was measured a rest and immediately when the 1-minute ended. The best performance of the two measurements was used which is widely used and serves as reference for evaluation of other devices. The handgrip strength test was done five consecutive times with the right hand, and 5 times with the left hand. As recommended, we used the best of the five measurements for each hand In brief, during ergometer cycling with incremental work load, the patient was monitored using electrocardiogram, oxygen consumption, carbon dioxide production, and blood pressure. Before and after the ride, a lung function test during maximal inspiration and expiration was performed. For each patient an overall conclusion was reported with was categorised as "normal Images were photographed at window settings appropriate for viewing the lung parenchyma (window level, −600 to −700 Hounsfield units [HU]; window width, 1200-1500 HU). Presence, extent, and distribution of prespecified radiological entities were evaluated. Analysed findings included ground-glass opacities, airspace consolidation, reticular pattern, pleuraparenchymal bands, mosaic, air trapping, interlobular septal thickening, traction bronchiectasis and traction bronchiolectasies provide a brief (<20 minutes) objective performance-based assessment of cognitive functions, including verbal learning and memory, working memory, psychomotor speed and executive function. SCIP total scores reflect a global measure of cognition, spanning verbal learning and memory, working memory and psychomotor speed. TMT-B scores are a measure of executive function A parameter of heart rate variability called deceleration capacity (DC) as well as periodic changes in T-waves termed periodic repolarization dynamics (PRD) were calculated. Both correlated to underlaying autonomous nerval system function DC < 2.5 ms or PRD > 5.75 degree was considered pathological. Supplemental Results: Cognitive function Patients who had been hospitalised displayed poorer psychomotor speed (SCIP test 5; t=-2.58, df=43, p=0.01) and executive function (TMT-B; t= 2.76, df=43, p=0.01) than non-hospitalised patients. There was also a strong trend toward more global cognitive impairment in hospitalised versus non-hospitalised patients (SCIP Total Scores: t=-1.75, df=43, p=0.054). However, after adjustment for age and sex, the group differences on these measures rendered non-significant (p-values>0.12). The poorer psychomotor speed and executive function in patients who had been hospitalised were driven by their older age (p-values≤0.03). Adjustment for age and sex revealed a strong trend towards more impaired verbal fluency in hospitalised vs Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper The MRC breathlessness scale. Occupational medicine The Validity and Reproducibility of a Work Productivity and Activity Impairment Instrument EQ-5D-5L user guide. Basic information on how to use the EQ-5D-5L instrument The post-COVID-19 functional status scale: A tool to measure functional status over time after COVID-19 The cognitive failures questionnaire (CFQ) and its correlates The one repetition maximum test and the sit-to-stand test in the assessment of a specific pulmonary rehabilitation program on peripheral muscle strength in COPD patients Handgrip dynamometry in healthy adults Standards for the use of cardiopulmonary exercise testing for the functional evaluation of cardiac patients: A report from the Exercise Physiology Section of the European Association for Cardiovascular Prevention and Rehabilitation Cardiopulmonary exercise testing and its application